Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | PKM | P14618 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5307153 | 0.80 | SMN1; SMN2 (0.79) | LMNASMN1; SMN2PKMKDM4EGAA | |
| SCHEMBL4616398 | 0.77 | SMN1; SMN2 (0.62) | LMNASMN1; SMN2PKMKDM4EALDH1A1 | |
| SCHEMBL4617500 | 0.77 | LMNA (0.43) | LMNASMN1; SMN2PKMKDM4EGAA | |
| SCHEMBL2316901 | 0.75 | CYP2D6 (0.82) | LMNAKDM4EGAAALDH1A1MAPK1 | |
| SCHEMBL13959171 | 0.73 | SMN1; SMN2 (0.73) | LMNASMN1; SMN2PKMKDM4EGAA | |
| SCHEMBL25138819 | 0.72 | POLB (0.72) | LMNASMN1; SMN2PKMKDM4EGAA | |
| SCHEMBL13973341 | 0.71 | SMN1; SMN2 (0.74) | LMNASMN1; SMN2PKMKDM4EGAA | |
| SCHEMBL16797500 | 0.71 | HPGD (0.58) | LMNAPKMGAAALDH1A1POLB | |
| SCHEMBL108678 | 0.71 | KDM4E (0.70) | KDM4EMAPK1TSHRMEN1KMT2A | |
| SCHEMBL247294 | 0.71 | PKM (1.00) | LMNASMN1; SMN2PKMKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | LMNA 4608/4885SMN1; SMN2 2404/4885PKM 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.